GLP-1 Adherence, Not Prescriptions: The Metabolic-Risk Signal Life Reinsurers Need

GLP-1 adherence, not prescription counts, is the metabolic-risk signal life reinsurers actually need. A filled script says a doctor wrote a prescription; sustained refill patterns say whether the insured's metabolic health is genuinely improving. For life treaty underwriters pricing mortality risk on portfolios where GLP-1 use is rising fast, adherence is the variable that separates improved risk from the illusion of treatment.

Why has GLP-1 adherence become the real signal for life reinsurance mortality pricing?

GLP-1 adherence has become the real signal because prescription counts create a misleading picture of metabolic risk. A cedent reports that 12% of its insured lives hold a GLP-1 prescription, but adherence data reveals that fewer than half fill that prescription consistently beyond six months. The mortality risk sits in the non-adherent cohort, not the prescription cohort.

Life reinsurance has always priced metabolic risk through traditional markers: BMI, HbA1c, blood pressure, and cholesterol. But GLP-1 drugs disrupt those signals. A treated applicant presents lab values that look controlled, yet if they discontinue the drug, metabolic parameters often rebound within months. Mortality improvement tables calibrated on pre-GLP-1 populations do not capture this pattern, and reinsurers relying on prescription counts alone are pricing unknown risk with outdated assumptions. The individual life reinsurance mortality data landscape is shifting, and adherence is the variable that makes sense of it.

For life treaty underwriters, this changes the submission conversation. The question is no longer "what share of your book uses GLP-1?" but "what share of your GLP-1 lives are actually adherent, and how does mortality experience differ between those two cohorts?" Cedents who can answer that question earn sharper pricing. Those who cannot are priced as if every GLP-1 user represents the same unresolved metabolic risk, and with an emerging risks watchlist growing longer each year, reinsurers have less patience for portfolios that cannot demonstrate treatment-effect durability.

What goes wrong when life reinsurers price GLP-1 portfolios on prescription counts alone?

Pricing on prescription counts fails in five ways: prescriptions overstate treatment engagement, claims data misses adherence gaps, non-adherent lives get pooled with adherent ones and drag assumptions down, portfolio-level aggregates hide behavioral heterogeneity, and mortality assumptions based on clinical-trial adherence do not survive real-world compliance.

Life treaty portfolios are accumulating GLP-1 exposure faster than underwriting manuals can adapt. Each failure mode below explains why adherence, not the script, is what separates a portfolio worth writing from one worth questioning.

1. How do prescription counts overstate the true treatment population?

Prescription counts overstate the true treatment population because a significant proportion of scripts are never filled, and among those that are filled, adherence drops sharply after three to six months. The mortality risk in a portfolio looks broader on paper than it actually is in the pharmacy.

A life reinsurer scanning a portfolio that reports 20% GLP-1 use may assume one-fifth of the book carries treated metabolic risk. But if only 9% are adherent at twelve months, the other 11% represent lives whose metabolic parameters are likely worsening, not improving, and the portfolio's true mortality profile splits into two very different sub-cohorts. An AI-powered treaty data quality checker would flag that discrepancy immediately, but a traditional prescription-count submission never surfaces it.

2. Why do pharmacy claims miss the adherence story?

Pharmacy claims miss the adherence story because they record fills, not consumption, and they rarely capture the reasons a patient stops. Without refill-gap analysis, a life with six months of fills looks identical to one with two years of uninterrupted therapy.

The difference matters for mortality pricing. A short GLP-1 course followed by discontinuation is often associated with weight regain and worsening glycemic control, exactly the trajectory that increases mortality risk relative to a never-treated peer. Reinsurers who see only the initial script, without longitudinal fill data, are pricing a treated life that no longer exists. Cedents equipped with treaty pricing intelligence that ingests adherence cohorts are in a far stronger position to argue for differentiated mortality assumptions.

3. How does pooling adherent and non-adherent lives distort mortality assumptions?

Pooling adherent and non-adherent lives distorts mortality assumptions because the average masks two populations with radically different risk profiles. The life treaty that prices all GLP-1 users at a single mortality adjustment is systematically mispricing both groups.

If adherent GLP-1 users genuinely experience lower mortality, and non-adherent users experience higher mortality due to metabolic rebound, a pooled assumption overcharges for the first group and undercharges for the second. The result is a portfolio that looks correctly priced on aggregate but hides cross-subsidies that erode profitability when claims emerge from the non-adherent tail. Historical treaty performance analysis that segments by adherence would expose this pattern, but most treaties are not yet monitored that way.

4. Why does behavioral heterogeneity matter more than the prescription?

Behavioral heterogeneity matters more than the prescription because adherence is a behavioral signal, not a pharmacological one. A life that fills a GLP-1 script consistently for two years is also likely to attend preventive screenings, follow dietary guidance, and comply with other therapies, all of which compound the mortality benefit.

Conversely, a life that abandons GLP-1 after two months is signaling something broader about engagement with care, and that signal correlates with worse outcomes across multiple dimensions. The reinsurance risk aggregation challenge is that most cedents do not collect this behavioral data at scale, so the signal exists only in external pharmacy databases, not in the submission data room.

5. What happens when clinical-trial adherence is assumed in a real-world portfolio?

When clinical-trial adherence is assumed in a real-world portfolio, mortality expectations systematically overshoot. Trial participants are monitored, supported, and selected; real-world patients discontinue at rates two to three times higher. Treaties built on trial-grade adherence assumptions are under-reserving from day one.

This is the emerging risk dimension of the GLP-1 story. A tidal wave of new indications, oral formulations, and direct-to-consumer prescribing will push real-world adherence even further from trial benchmarks. The reinsurer that prices today's portfolio on trial data will find itself chasing experience that diverges in both directions: lower mortality than expected among the truly adherent, and higher mortality among the majority who are not.

Move beyond prescription counts to real adherence intelligence for your life treaty portfolio

Talk to Our Specialists

Visit Insurnest to learn how we help life reinsurers and cedents build adherence-based mortality segmentation that earns better treaty terms.

What do life treaty underwriters actually expect from GLP-1 data at submission?

Underwriters expect not just a count of GLP-1 prescriptions in the portfolio but a stratification by adherence duration, an analysis of how mortality experience differs by cohort, evidence that data is refreshed and not rolled forward, disclosure of the non-adherent share, and a credible methodology for translating adherence signals into mortality assumptions.

It is four weeks before the January 1 renewal. A life treaty underwriter at a European reinsurer, Michael Okonkwo, is reviewing a submission from a mid-sized life carrier whose portfolio shows a sharp rise in GLP-1 prescriptions over two years. The submission reports the prescription prevalence, but nothing about adherence. Michael's modeling team flags the gap: the carrier's mortality assumptions appear to assume sustained GLP-1 benefit, yet the pharmacy claims the carrier shared last year showed a six-month persistence rate below fifty percent.

Michael wants the conversation to change. He wants the cedent to come to the table with adherence-stratified exposure data, so his pricing reflects the portfolio's actual risk distribution, not a single blended assumption that over-credits treatment effect. He wants the carrier to show that it controls the data, not just reports it.

That is the real expectation today. Beneath the technical language sit concrete asks that life treaty underwriters now bring to every submission.

• Adherence-stratified exposure data. "Don't tell me how many prescriptions were written. Tell me how many lives filled consistently at six, twelve, and twenty-four months." An undifferentiated prescription count is no longer a submission asset.
• Mortality experience by adherence cohort. "Show me your actual-to-expected experience for adherent versus non-adherent GLP-1 lives, even if credibility is thin." The direction of the signal matters as much as statistical significance.
• Refill-gap methodology disclosed and consistent. "Explain how you define a gap, what window you use, and whether partial fills count." Without methodological transparency, the adherence measure cannot be compared across portfolios.
• Evidence that data is current, not rolled forward from prior year. "Prove the adherence view reflects this year's pharmacy claims, not last year's file re-dated." Portfolios where adherence data never changes signal passive data management, not active monitoring.
• Disclosure of the non-adherent share with reasons where available. "Flag what you know about why lives discontinue: cost, side effects, or lost-to-follow-up." The reason for non-adherence changes the mortality implication, and reinsurers know it.
• Segmentation by drug type and dosage tier. "Separate semaglutide from tirzepatide, starter doses from maintenance doses." Different molecules and doses carry different persistence profiles, and a single GLP-1 bucket obscures those differences.
• Comorbidity context on GLP-1 lives. "Tell me whether these lives are on GLP-1 for obesity alone or for diabetes with cardiovascular disease." The underlying condition drives the mortality baseline, and the GLP-1 is a modifier, not a substitute for that context.
• A view of new GLP-1 starts and discontinuations between renewals. "Show me the flow: how many lives entered GLP-1 therapy this year, how many left it." Stock-and-flow analysis reveals whether the portfolio's adherence profile is improving or deteriorating.
• Pharmacoeconomic context on affordability risk. "Are your lives paying out-of-pocket, or is this employer-covered?" Cost-driven non-adherence is a macro risk that grows as GLP-1 demand strains benefit budgets, and it will hit some portfolios harder than others.
• Willingness to share adherence data between renewals. "Can I see a mid-year adherence snapshot, or do you only produce this data at renewal time?" Real-time monitoring signals a cedent that actively manages the risk rather than packaging it annually.
• A credible bridge from adherence to mortality assumptions. "Walk me through how your adherence data informs your mortality improvement assumption, not just qualitatively but in the model." The bridge is what converts data into pricing, and underwriters want to see it.

The real expectation is not perfect adherence data across every life. It is measured, disclosed, longitudinal data, presented by a cedent who has already asked the hard questions before the underwriter does.

How can life reinsurers build adherence-based mortality segmentation?

Life reinsurers can build adherence-based mortality segmentation by integrating pharmacy claims with mortality monitoring, defining adherence cohorts with clear persistence thresholds, adjusting mortality assumptions by cohort, tracking adherence dynamics between renewals, establishing data-sharing protocols with cedents, and building the analytical infrastructure that turns refill patterns into treaty-level pricing signals.

This is where technology turns those underwriter expectations into a structured capability. Each ask above maps to a component a reinsurer or cedent can build, described below.

1. How does pharmacy-claims integration unlock the adherence signal?

Pharmacy-claims integration unlocks the adherence signal by linking each insured life to its longitudinal fill history, so the reinsurer can calculate persistence rates, refill gaps, and adherence trajectories rather than relying on a single prescription flag captured at underwriting.

The technical lift is not trivial. Pharmacy data arrives in formats designed for reimbursement, not risk analytics. NDC codes must be mapped to drug classes, fill dates converted to adherence windows, and lives matched across pharmacy benefit manager and insurer records. But once built, the pipeline answers questions that prescription counts never can: what share of GLP-1 lives are still filling at month twelve, and how does their mortality look? AI in term life insurance applications are making this integration faster than manual matching ever could.

2. What makes a credible adherence cohort definition for reinsurance?

A credible adherence cohort definition uses clear, replicable thresholds: sustained adherent at twelve months, intermittent with at least one gap exceeding thirty days, and discontinued with no fill in the trailing six months. The definition must be consistent across reporting periods so year-over-year comparisons hold.

Cohort definitions that shift at every renewal destroy the analytical value of adherence data. A treaty pricing framework built around proportional reinsurance structures benefits from cohort stability because ceded premium shares track the underlying risk distribution. Adherence cohorts that are auditable and stable give both cedent and reinsurer a shared language for what "adherent" means in the portfolio.

3. How does mortality-experience monitoring by adherence cohort work?

Mortality-experience monitoring by adherence cohort works by tagging each death in the portfolio with its GLP-1 adherence status at the last observation before death, then calculating actual-to-expected ratios separately for adherent, intermittent, and non-adherent cohorts against a common mortality table.

Even with limited deaths in early years, the pattern is what matters. If the non-adherent cohort consistently shows higher mortality than the adherent cohort, the reinsurer can adjust assumptions with credibility weighting rather than waiting for statistical significance. A historical treaty performance analyzer configured for adherence segmentation makes this monitoring a recurring output rather than an ad hoc study.

4. Why do adherence dynamics between renewals matter for treaty terms?

Adherence dynamics between renewals matter because a portfolio that is losing adherent lives and gaining non-adherent ones between treaty periods carries a deteriorating risk profile that the last renewal's data does not yet reflect.

A quarterly adherence snapshot reveals whether the GLP-1 cohort is stabilizing or churning. If a cedent's portfolio shows that 30% of adherent lives drop off between quarters, the reinsurer needs to price that churn into the mortality assumption, not discover it in claims experience two years later. The reinsurance market cycle amplifies this: in a hardening market, undetected deterioration gets priced into next year's terms anyway, but the cedent that catches it early has time to adjust.

5. What data-sharing protocols make adherence monitoring practical?

Data-sharing protocols make adherence monitoring practical by defining what pharmacy data the cedent shares, in what format, at what frequency, with what life-matching key, and under what confidentiality terms, so the reinsurer can run the analysis without a data-engineering project every quarter.

The protocol should specify NDC-to-drug-class mapping, adherence window definitions, minimum cohort sizes below which data is suppressed, and a process for reconciling pharmacy records with policy administration data. Bordereaux automation technology can transform what was once a quarterly spreadsheet exercise into a structured data feed that both parties trust.

6. How does the analytical infrastructure connect adherence to treaty pricing?

The analytical infrastructure connects adherence to treaty pricing by ingesting the adherence-stratified exposure and mortality data, fitting cohort-level mortality assumptions within the treaty model, producing scenario tests around adherence deterioration, and outputting a priced cession that reflects the portfolio as it actually behaves rather than as a single blended assumption.

This is the endpoint of the pipeline: an AI-powered treaty pricing model that accepts adherence cohorts as an input variable, weights them by credibility, and generates premium, commission, and loss-ratio projections that explicitly account for the difference between adherent and non-adherent mortality experience. When Michael's cedent comes to the table with that analysis, the pricing conversation shifts from "do we believe your GLP-1 data" to "let us calibrate the cohort adjustment," which is exactly where both parties want to be.

Build adherence-based mortality segmentation with Insurnest's life reinsurance technology

Talk to Our Specialists

Visit Insurnest to see how we deliver pharmacy-claims integration, adherence cohort monitoring, and treaty pricing analytics built for the GLP-1 era of life reinsurance.

What does an ideal GLP-1-informed life treaty submission look like?

An ideal GLP-1-informed life treaty submission presents adherence-stratified exposure with clear cohort definitions, mortality experience split by adherence status, churn analysis showing cohort flows between renewals, disclosed methodology, and a bridge document that walks from adherence data to the proposed mortality assumption.

Return to Michael at his desk. This time, the submission from the same life carrier arrives differently. The first page of the exposure summary shows GLP-1 lives segmented into three adherence tiers: sustained, intermittent, and discontinued, with counts, average sum assured, and two-year mortality experience per tier. The methodology appendix defines every threshold. The bridge document shows how the carrier arrived at its proposed mortality improvement assumption for each cohort, referencing its own experience and external benchmarks.

In the meeting, when Michael asks about the 40% non-adherent share, the carrier's ceded re team shows the churn analysis: new starts, discontinuations, and net change per quarter. They explain that most discontinuations are cost-driven and that the carrier is piloting an adherence-support program that may improve these numbers next year. The conversation is about risk management, not about whether the data is real.

That is the goal. A submission that treats GLP-1 adherence as a trackable, segmentable risk driver rather than a single-line exposure count. Cedents who reach that standard earn pricing that reflects their portfolio's actual behavior, and in a market where uncertainty loads are rising, that differential is material. The longevity reinsurance market is learning the same lesson from the opposite direction: treatment adherence is a mortality signal that works in both tails.

Turn GLP-1 prescription data into a treaty pricing advantage with Insurnest

Talk to Our Specialists

Visit Insurnest to learn how we help life reinsurers and cedents build adherence-stratified mortality analytics that win better treaty terms.

Conclusion

For life treaty underwriters and their cedents, GLP-1 adherence has become the variable that turns prescription exposure data from a liability into an asset. Prescription counts describe the treated population on paper; adherence data describes the population whose metabolic risk is actually changing, and in which direction.

For ceded reinsurance teams at life carriers, the opportunity is clear. Building pharmacy-claims integration, defining stable adherence cohorts, monitoring mortality by cohort, and presenting the analysis at submission converts what is currently a data gap into a pricing differentiator. The work is analytical and repeatable, not a one-time study, and it rewards consistency.

The GLP-1 era in life reinsurance is not about whether these drugs work. It is about whether the portfolio data can prove who is actually taking them, and for how long. Adherence is the answer, and the treaties that incorporate it will be priced more accurately, more transparently, and with less friction than those that still count scripts and hope for the best.

Frequently asked questions

What is the difference between GLP-1 prescription data and adherence data for reinsurers?

Prescription data captures whether a drug was written; adherence data measures whether the insured fills and takes it consistently. Adherence reveals behavior patterns that prescription counts obscure, making it the stronger mortality signal for underwriting.

Why does GLP-1 adherence matter more than prescription counts for mortality risk assessment?

GLP-1 adherence signals whether a patient is managing their metabolic condition consistently. Sporadic use often correlates with broader non-adherence to care, which predicts worse health outcomes more reliably than a filled prescription ever can.

How do GLP-1 adherence patterns affect life reinsurance underwriting?

Reinsurers evaluating adherence patterns can better distinguish between applicants whose metabolic risk is genuinely improving on sustained therapy and those whose prescription history creates an illusion of treatment without real health improvement.

What real-world evidence sources can reinsurers use to track GLP-1 adherence?

Pharmacy claims databases, employer-sponsored health plan data, and pharmacy benefit manager records provide longitudinal fill-and-refill patterns that reveal whether GLP-1 therapy is sustained or interrupted over meaningful time horizons.

How does poor GLP-1 adherence signal underlying metabolic risk?

Poor GLP-1 adherence often signals broader metabolic dysfunction: patients who cannot sustain therapy despite prescriptions typically exhibit higher HbA1c, weight regain, and elevated cardiovascular risk that aggregated claims miss but mortality models should capture.

Can life reinsurers differentiate between short-term and sustained GLP-1 use?

Yes, by analyzing refill intervals and gaps, reinsurers can distinguish continuous therapy from episodic use. Sustained adherence correlates with normalized metabolic markers, while fragmented use suggests unresolved risk that still affects mortality expectations.

What data quality issues affect GLP-1 adherence measurement in insurance?

Pharmacy claims often lack dose-titration detail and reasons for discontinuation. Claims-level adherence proxies, such as proportion of days covered, are sensitive to data completeness and can misrepresent true adherence without clinical context.

How should reinsurers incorporate GLP-1 adherence into treaty pricing?

Reinsurers should stratify portfolio mortality assumptions by adherence pattern cohorts, apply credibility-weighted adjustments for sustained versus interrupted GLP-1 use, and require cedents to report adherence segments not simply prescription counts in their exposure data.

About the author

Hitul Mistry is the Founder of Insurnest, an InsurTech company that engineers end-to-end technology exclusively for the insurance industry serving carriers, TPAs, MGAs, brokers, and reinsurers across India, the UAE, and the US. With more than a decade of insurance domain experience, he has built systems spanning underwriting automation, AI-powered underwriting intelligence, claims management, rating and quoting, broking and agency platforms, and reinsurance automation across Health/GMC, Group Life, Motor, P&C, and Reinsurance. Insurnest doesn't adapt generic software to insurance; it builds from the workflow up.

Connect with Hitul on LinkedIn.